Naloxon

Naloxone Struktur
465-65-6
CAS-Nr.
465-65-6
Bezeichnung:
Naloxon
Englisch Name:
Naloxone
Synonyma:
Naloxone impurity;C07252;NALOXONE;NSC 70413;l-naloxone;Naloxone API;-bcd)furanone;Naloxone Base;,5-bcd)furanone;Naloxone (125 mg)
CBNumber:
CB5728727
Summenformel:
C19H21NO4
Molgewicht:
327.37
MOL-Datei:
465-65-6.mol

Naloxon Eigenschaften

Schmelzpunkt:
184° (Lewenstein), 177-178° (Sankyo Co.)
alpha 
D20 -194.5° (c = 0.93 in CHCl3)
Siedepunkt:
465.27°C (rough estimate)
Dichte
1.2223 (rough estimate)
Brechungsindex
1.5000 (estimate)
Flammpunkt:
9℃
storage temp. 
2-8°C
Löslichkeit
Chloroform (Slightly, Heated, Sonicated), DMSO (Slightly), Methanol (Slightly),
Aggregatzustand
Solid
pka
pKa 7.94/7.82(H2O,t =20/37,I<0.01) (Uncertain)
Farbe
White to Off-White
InChIKey
UZHSEJADLWPNLE-GRGSLBFTSA-N
EPA chemische Informationen
Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5.alpha.)- (465-65-6)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Kennzeichnung gefährlicher F,T
R-Sätze: 11-23/24/25-39/23/24/25
S-Sätze: 7-16-36/37-45
RIDADR  UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany  3
HS Code  2939190000
Giftige Stoffe Daten 465-65-6(Hazardous Substances Data)
Toxizität An opiate antagonist devoid of agonist activity except for mild, specific effects at very high doses. Naloxone displays a high affinity for the μ-opioid receptor, a lesser affinity for the kopioid receptor and has some affinity for δ-opioid receptor subtypes. Naloxone produces a rapid and profound reversal of the effects of opioid administration (e.g., 1 mg, i.v., blocks the effects of 25 mg of heroin). Naloxone also antagonizes the analgesia induced by placebo, acupuncture, and stress, and in animals the hypotension due to hypovolemia or spinal cord injury. Naloxone has a short half-life (about 1 h in plasma) and is not administered orally because of rapid, “first-pass” metabolism.
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitsschädlich bei Verschlucken. Akute Toxizität oral Kategorie 4 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P270, P301+P312, P330, P501
Sicherheit
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P270 Bei Gebrauch nicht essen, trinken oder rauchen.
P301+P312 BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.
P501 Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Naloxon Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

It is worth mentioning that N-allylic substitution in a number of morphine derivatives, as a rule, leads to antagonistic properties. Naloxone is a few times stronger than nalorphine as an antagonist. It blocks opiate receptors. It eliminates central and peripheral action of opioids, including respiratory depression. Naloxone is used upon overdose of narcotic analgesics.

Verwenden

Naloxone is a specific opioid antagonist. Narcotic antagonist.

Definition

ChEBI: A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an all l group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.

Biologische Funktion

Because of its fast onset (minutes), naloxone (Narcan) administered IV is used most frequently for the reversal of opioid overdose. However, it fails to block some side effects of the opioids that are mediated by the δ- receptor, such as hallucinations. The rapid offset of naloxone makes it necessary to administer the drug repeatedly until the opioid agonist has cleared the system to prevent relapse into overdose. The half-life of naloxone in plasma is 1 hour. It is rapidly metabolized via glucuronidation in the liver and cleared by the kidney. Naloxone given orally has a large first-pass effect, which reduces its potency significantly. Often an overshoot will follow the administration of naloxone for overdose. The heart rate and blood pressure of the patient may rise significantly. The overshoot is thought to be due to precipitation of acute withdrawal signs by naloxone. Given alone to nonaddicts, naloxone produces no pharmacological effects.
Naloxone is approved for use in neonates to reverse respiratory depression induced by maternal opioid use. In addition, naloxone has been used to improve circulation in patients in shock, an effect related to blockade of endogenous opioids. Other experimental and less well documented uses for naloxone include reversal of coma in alcohol overdose, appetite suppression, and alleviation of dementia from schizophrenia. Side effects of naloxone are minor.

Allgemeine Beschreibung

Naloxone (Narcan) is a pure antagonist at allopioid receptor subtypes. Structurally, it resembles oxymorphoneexcept that the methyl group on the nitrogen isreplaced by an allyl group. This minor structural change retains high binding affinity to the receptor, but no intrinsicactivity. It is used to reverse the respiratory depressant effectsof opioid overdoses.
Naloxone is administered intravenously with an onset ofaction within 2 minutes. Because it is competing with theopioid for the receptor sites, the dose and frequency of administrationwill depend on the amount and type of narcoticbeing antagonized. Overdoses of long-acting opioids(methadone) may require multiple IV doses of naloxone orcontinuous infusions. Neonates born to opioid-exposedmothers may be given IV naloxone at birth to reverse the effectsof opiates.
Very few metabolism studies on naloxone have beenconducted, although the major metabolite found in the urineis naloxone-3-glucuronide.

Naloxon Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Naloxon Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 63)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21695 55
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28180 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 47465 58
Shaanxi Dideu Medichem Co. Ltd
+86-029-89586680 +86-18192503167
1026@dideu.com China 9553 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 29474 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471
sales@sarms4muscle.com China 10523 58
LEAP CHEM CO., LTD.
+86-852-30606658
market18@leapchem.com China 24738 58
Shanghai Acmec Biochemical Technology Co., Ltd.
+undefined18621343501
product@acmec-e.com China 33349 58
Aladdin Scientific
+1-833-552-7181
sales@aladdinsci.com United States 57511 58
Chemwill Asia Co.,Ltd. 86-21-51086038
chemwill_asia@126.com CHINA 23931 58

465-65-6(Naloxon)Verwandte Suche:


  • 12-allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4ah-8,9c-iminoethanophenanthro(4,5
  • 12-allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4ah-8,9c-iminoethanophenanthro[4,5
  • 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-morphinan-6-on
  • 17-allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one
  • 17-allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
  • 1-n-allyl-14-hydroxynordihydromorphinone
  • 1-n-allyl-7,8-dihydro-14-hydroxynormorphinone
  • 4,5-alpha-epoxy-3,14-dihydroxy-17-(2-propenyl)-morphinan-6-on
  • 5-epoxy-3,14-dihydroxy-17-(2-propenyl)-(5alpha)-morphinan-6-on
  • -bcd)furanone
  • -bcd]furan-5(6h)-one
  • l-n-allyl-14-hydroxynordihydromorphinone
  • l-n-allyl-7,8-dihydro-14-hydroxynormorphinone
  • l-naloxone
  • n-allyl-noroxymorphone
  • 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one
  • 9: PN: WO03037310 FIGURE: 4 claimed sequence
  • Morphinan-6-one, 17-allyl-4,5a-epoxy-3,14-dihydroxy- (8CI)
  • Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5a)- (9CI)
  • Normorphinone, N-allyl-7,8-dihydro-14-hydroxy- (7CI)
  • NSC 70413
  • (5alpha)-3,14-Dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one
  • (4R)-6,10aβ-Dihydroxy-11-allyl-4α,5-epoxy-10β,4aβ-(epiminoethano)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-3-one
  • 17-Allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
  • C07252
  • Naloxone (125 mg)
  • Methanol (test Naloxone, 1.0 mg/mL)
  • Naloxone Base
  • Morphinan-6-one,4,5-epoxy-3,14-dihydroxy-17-(2-propen-1-yl)-, (5a)-
  • Naloxone solution
  • (5α)-4,5-Epoxy-3,14-dihydroxy-17-(2-propen-1-yl)morphinan-6-one
  • Naloxone, (controlled)
  • Nafoxone Hydrochloride
  • NALOXONE
  • ,5-bcd)furanone
  • 12-allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4ah-8,9c-iminoethanophenanthro(4
  • Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propen-1-yl)-, (5α)-
  • Naloxone USP/EP/BP
  • Naloxone (1.0 mg/mL in Methanol)
  • Naloxone API
  • Naloxone (1453005)
  • Naloxone impurity
  • 465-65-6
  • Isotopically Labeled Pharmaceutical Reference Standard
  • AMPLIMEXON
Copyright 2019 © ChemicalBook. All rights reserved